GlassScriptPhysician profile
Jeffrey D Robbins
NPI 1669408514
$8,751.84
in general payments reported to CMS, 2019-2025
62 companies · $1,616 in 2025
The $1,616 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,104 · 2022: $2,087 · 2023: $1,955 · 2024: $1,989 · 2025: $1,616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,560.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,642.44 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $863.81 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $773.28 | 2021-2024 | Repatha, Otezla, Prolia |
| Lilly USA, LLC | $525.70 | 2021-2025 | Mounjaro, Emgality, Jardiance |
| Pfizer INC. | $468.35 | 2021-2025 | |
| Novo Nordisk INC | $409.93 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.10 | 2021-2025 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $211.13 | 2021-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $197.95 | 2022-2025 | |
| Antares Pharma, INC. | $195.67 | 2024-2025 | Xyosted |
| Corium, LLC | $183.45 | 2022-2025 | Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $177.47 | 2021-2024 | |
| Supernus Pharmaceuticals, INC. | $167.37 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $163.88 | 2021-2023 | Xarelto, Spravato |
| Neurocrine Biosciences, INC. | $155.24 | 2023-2024 | Ingrezza, Ongentys |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Robbins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.